Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05949099 · ClinicalTrials.gov registry record · Phase 2
Study of Cryoablation and Nirogacestat for Desmoid Tumor
A Phase 2 study of Desmoid Tumor, sponsored by Nam Bui.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05949099 is a Phase 2 study of Desmoid Tumor that is actively recruiting participants, run by Nam Bui. The registered enrollment target is 28 participants, below the 83-participant average among 4 other Desmoid Tumor trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05949099, a Phase 2 study of Desmoid Tumor, is actively recruiting participants, sponsored by Nam Bui.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.
Conditions Studied
Interventions
- PROCEDURE Cryoablation
- DRUG Nirogacestat
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05949099
The ClinicalTrials.gov registry entry for NCT05949099 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 4 other Desmoid Tumor trials with a reported enrollment target (66% lower). The listed sponsor is Nam Bui, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Desmoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Cryoablation is the first listed.
NCT05949099 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05949099 about?
NCT05949099 is a clinical study titled "Study of Cryoablation and Nirogacestat for Desmoid Tumor". The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.
What is the current status of trial NCT05949099?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-08-15. Estimated completion is 2028-02-01.
What conditions does trial NCT05949099 study?
This clinical trial studies the following conditions: Desmoid Tumor.
What interventions are being tested in trial NCT05949099?
The interventions under investigation include: Cryoablation (PROCEDURE), Nirogacestat (DRUG).
Who is sponsoring clinical trial NCT05949099?
This trial is sponsored by Nam Bui, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05949099 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Desmoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AL102 in Patients With Progressing Desmoid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
COMPLETED · Phase 2
-
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
COMPLETED · Phase 2
-
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.